PA
ZYNE

Perceptive Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Perceptive Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200,000
Closed -$790K – 135
2019
Q4 		$790K Hold
200,000
– – 0.02% 101
2019
Q3 		$635K Buy
+200,000
New +$2.25M 0.02% 95
2017
Q3 		– Sell
-100,000
Closed -$10.2M – 158
2017
Q2 		$10.2M Buy
+100,000
New +$1.99M 0.51% 47

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Perceptive Advisors's ZYNE Position: Q4 2017 in Review

Perceptive Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2017, closing a stake of 130,700 shares — an estimated $1.32M sold.

Perceptive Advisors first reported a position in ZYNE in Q3 2015 and held it in 8 quarters. The position peaked at $13.1M in Q4 2016. 64 funds tracked by Wall St. Rank hold ZYNE as of Q4 2017.

  • Perceptive Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2017 after selling out during the quarter.
  • Perceptive Advisors sold 130,700 Zynerba Pharmaceuticals, Inc shares in Q4 2017, an estimated $1.32M.
  • Perceptive Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 8 quarters.
  • Perceptive Advisors's Zynerba Pharmaceuticals, Inc position peaked at $13.1M in Q4 2016.
  • 64 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2017.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.